Coward, J.I.; Barve, M.A.; Kichenadasse, G.; Moore, K.N.; Harnett, P.R.; Berg, D.; Garner, J.S.; Dizon, D.S.
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers 2021, 13, 3196.
https://doi.org/10.3390/cancers13133196
AMA Style
Coward JI, Barve MA, Kichenadasse G, Moore KN, Harnett PR, Berg D, Garner JS, Dizon DS.
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers. 2021; 13(13):3196.
https://doi.org/10.3390/cancers13133196
Chicago/Turabian Style
Coward, Jermaine I., Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel Berg, James S. Garner, and Don S. Dizon.
2021. "Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results" Cancers 13, no. 13: 3196.
https://doi.org/10.3390/cancers13133196
APA Style
Coward, J. I., Barve, M. A., Kichenadasse, G., Moore, K. N., Harnett, P. R., Berg, D., Garner, J. S., & Dizon, D. S.
(2021). Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers, 13(13), 3196.
https://doi.org/10.3390/cancers13133196
